> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Azar Expected to be Named HHS Secretary: Bloomberg
- URL: https://www.fdaweb.com/azar-expected-to-be-named-hhs-secretary-bloomberg/
- Published: 2017-11-09T12:00:00.000Z
- Updated: 2026-09-14T23:01:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140100

Bloomberg News [reports](https://www.bloomberg.com/news/articles/2017-11-09/trump-said-to-name-ex-lilly-executive-azar-as-health-secretary?ref=fdaweb.com) that former Eli Lilly executive **Alex Azar** is expected to be named HHS secretary, replacing former Rep. **Tom Price**, who resigned after his extensive use of private and military jets at taxpayer expense was documented. Bloomberg cautioned that President **Donald Trump** is in the midst of an extended trip in Asia and could change his mind before a replacement is officially named.

Before joining Lilly, Azar was a deputy HHS secretary under former President **George W. Bush**.

Earlier rumors of an Azar appointment drew [ire](https://www.fdaweb.com/public-citizen-warns-against-azar-at-hhs/) from Public Citizen, which said that the appointment would mean “Big Pharma’s coup d’etat in the healthcare sphere will be virtually complete.” Public Citizen noted that Azar has made public statements indicating his opposition to measures to restrain drug company profiteering and limit improper marketing, while favoring weaker drug safety standards.